These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36571300)

  • 21. A naturalistic, 24-week, open-label, add-on study of vortioxetine in bipolar depression.
    Siwek M; Chrobak AA; Sołtys Z; Dudek D; Krupa AJ; Rybakowski JK
    Psychiatr Pol; 2022 Jun; 56(3):509-522. PubMed ID: 36342982
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis.
    Kishi T; Ikuta T; Sakuma K; Okuya M; Hatano M; Matsuda Y; Iwata N
    Mol Psychiatry; 2023 Jan; 28(1):402-409. PubMed ID: 36253442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of Vortioxetine Monotherapy for Posttraumatic Stress Disorder: A Randomized, Placebo-Controlled Trial.
    Dunlop BW; Rakofsky JJ; Newport DJ; Mletzko-Crowe T; Barone K; Nemeroff CB; Harvey PD
    J Clin Psychopharmacol; 2021 Mar-Apr 01; 41(2):172-179. PubMed ID: 33587394
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of vortioxetine in the treatment of neuropathic pain.
    Alcántara Montero A; Pacheco de Vasconcelos SR
    Rev Esp Anestesiol Reanim (Engl Ed); 2022 Dec; 69(10):640-648. PubMed ID: 36241510
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment effects on residual cognitive symptoms among partially or fully remitted patients with major depressive disorder: A randomized, double-blinded, exploratory study with vortioxetine.
    Nierenberg AA; Loft H; Olsen CK
    J Affect Disord; 2019 May; 250():35-42. PubMed ID: 30826492
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tolerability and efficacy of vortioxetine versus SSRIs in elderly with major depression. Study protocol of the VESPA study: a pragmatic, multicentre, open-label, parallel-group, superiority, randomized trial.
    Ostuzzi G; Gastaldon C; Barbato A; D'Avanzo B; Tettamanti M; Monti I; Aguglia A; Aguglia E; Alessi MC; Amore M; Bartoli F; Biondi M; Bortolaso P; Callegari C; Carrà G; Caruso R; Cavallotti S; Crocamo C; D'Agostino A; De Fazio P; Di Natale C; Giusti L; Grassi L; Martinotti G; Nosé M; Papola D; Purgato M; Rodolico A; Roncone R; Tarsitani L; Turrini G; Zanini E; Amaddeo F; Ruggeri M; Barbui C
    Trials; 2020 Aug; 21(1):695. PubMed ID: 32746941
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Successfully treated patients with vortioxetine versus venlafaxine: a simplified cost-effectiveness analysis based on a head-to-head study in Asian patients with major depressive disorder.
    Wang G; Zhao K; Reynaud-Mougin C; Loft H; Ren H; Eriksen HF; Ettrup A
    Curr Med Res Opin; 2020 May; 36(5):875-882. PubMed ID: 31990207
    [No Abstract]   [Full Text] [Related]  

  • 28. Vortioxetine Treatment for Depression in Patients with Prodromal vs Mild Alzheimer's Disease: A Six-Month, Open-Label, Observational Study.
    Padovani A; Caratozzolo S; Benussi A; Galli A; Rozzini L; Cosseddu M; Turrone R; Pilotto A
    J Prev Alzheimers Dis; 2024; 11(2):375-381. PubMed ID: 38374744
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder.
    Pae CU; Wang SM; Han C; Lee SJ; Patkar AA; Masand PS; Serretti A
    J Psychiatry Neurosci; 2015 May; 40(3):174-86. PubMed ID: 25350320
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trials.
    Berhan A; Barker A
    BMC Psychiatry; 2014 Sep; 14():276. PubMed ID: 25260373
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Paroxetine
    Callegari C; Ielmini M; Caselli I; Lucca G; Isella C; Diurni M; Pettenon F; Poloni N
    Psychopharmacol Bull; 2019 Feb; 49(1):28-43. PubMed ID: 30858637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Using early changes in cold cognition to predict response to vortioxetine in major depressive disorder.
    Park C; Zuckerman H; Subramaniapillai M; Mansur RB; Rosenblat JD; Cao B; Iacobucci M; Lee Y; Levitan R; Blumberger DM; McIntyre RS
    Psychiatry Res; 2020 Feb; 284():112767. PubMed ID: 31978627
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.
    Cipriani A; Furukawa TA; Salanti G; Chaimani A; Atkinson LZ; Ogawa Y; Leucht S; Ruhe HG; Turner EH; Higgins JPT; Egger M; Takeshima N; Hayasaka Y; Imai H; Shinohara K; Tajika A; Ioannidis JPA; Geddes JR
    Lancet; 2018 Apr; 391(10128):1357-1366. PubMed ID: 29477251
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vortioxetine versus Duloxetine in the Treatment of Patients with Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials.
    Li G; Wang X; Ma D
    Clin Drug Investig; 2016 Jul; 36(7):509-17. PubMed ID: 27067232
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Switching Strategies of Various Antidepressants to Vortioxetine in the PREDDICT Trial.
    Mills NT; Sampson E; Fourrier C; Baune BT
    Int J Neuropsychopharmacol; 2021 Apr; 24(4):314-321. PubMed ID: 33269395
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inclusion/exclusion criteria in placebo-controlled studies of vortioxetine: Comparison to other antidepressants and implications for product labeling.
    Zimmerman M; Clark HL; Multach MD; Walsh E; Rosenstein LK; Gazarian D
    J Affect Disord; 2016 Jan; 190():357-361. PubMed ID: 26546771
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vortioxetine for attention deficit hyperactivity disorder in adults: A randomized, double-blind, placebo-controlled, proof-of-concept study.
    Biederman J; Lindsten A; Sluth LB; Petersen ML; Ettrup A; Eriksen HF; Fava M
    J Psychopharmacol; 2019 Apr; 33(4):511-521. PubMed ID: 30843450
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The efficacy and safety of 5 mg/d Vortioxetine compared to placebo for major depressive disorder: A meta-analysis.
    Fu J; Chen Y
    Psychopharmacology (Berl); 2015 Jan; 232(1):7-16. PubMed ID: 24871704
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: A short-term, randomized, double-blind, exploratory study.
    Baune BT; Sluth LB; Olsen CK
    J Affect Disord; 2018 Mar; 229():421-428. PubMed ID: 29331703
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relative efficacy and tolerability of vortioxetine versus selected antidepressants by indirect comparisons of similar clinical studies.
    Llorca PM; Lançon C; Brignone M; Rive B; Salah S; Ereshefsky L; Francois C
    Curr Med Res Opin; 2014 Dec; 30(12):2589-606. PubMed ID: 25249164
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.